Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2016 Jul;14(7):825-36.
doi: 10.6004/jnccn.2016.0087.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

David S Ettinger  1 , Douglas E Wood  1 , Wallace Akerley  1 , Lyudmila A Bazhenova  1 , Hossein Borghaei  1 , David Ross Camidge  1 , Richard T Cheney  1 , Lucian R Chirieac  1 , Thomas A D'Amico  1 , Thomas Dilling  1 , Michael Dobelbower  1 , Ramaswamy Govindan  1 , Mark Hennon  1 , Leora Horn  1 , Thierry M Jahan  1 , Ritsuko Komaki  1 , Rudy P Lackner  1 , Michael Lanuti  1 , Rogerio Lilenbaum  1 , Jules Lin  1 , Billy W Loo Jr  1 , Renato Martins  1 , Gregory A Otterson  1 , Jyoti D Patel  1 , Katherine M Pisters  1 , Karen Reckamp  1 , Gregory J Riely  1 , Steven E Schild  1 , Theresa A Shapiro  1 , Neelesh Sharma  1 , Scott J Swanson  1 , James Stevenson  1 , Kurt Tauer  1 , Stephen C Yang  1 , Kristina Gregory  1 , Miranda Hughes  1
Affiliations
Guideline

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

David S Ettinger et al. J Natl Compr Canc Netw. 2016 Jul.

Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

PubMed Disclaimer

References

    1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576–588. - PubMed
    1. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081–2090. - PMC - PubMed
    1. Galateau-Salle F, Churg A, Roggli V, et al. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 Classification. J Thorac Oncol 2016;11:142–154. - PubMed
    1. Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854–861. - PubMed
    1. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:23–32. - PMC - PubMed

Publication types